April 4, 2025
The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is […]
April 4, 2025
Fatigue and frailty, two common comorbidities of inflammatory rheumatic diseases, often receive insufficient attention in rheumatologic care settings. Fatigue significantly reduces quality of life, while frailty […]
April 3, 2025
Nearly 2 years after entering the market, adalimumab biosimilars are finally seeing traction. CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, which are pharmacy […]
April 3, 2025
TOPLINE Patients with moderate to severe active systemic lupus erythematosus (SLE) who began treatment with anifrolumab in the TULIP-1 and TULIP-2 trials experienced a statistically significant […]
April 2, 2025
TOPLINE: A systematic review of randomized clinical trials (RCTs) on idiopathic inflammatory myopathies (IIMs) found that race was not appropriately reported in nearly half of the […]
April 1, 2025
Preliminary safety data from a French registry on combination therapy in immune-mediated inflammatory diseases (IMIDs) show a concerning rate of serious infections and illustrate the need […]
April 1, 2025
When patients with inflammatory arthritis develop an infection while taking immunomodulatory drugs, temporarily interrupting the therapy does not improve outcomes, according to results from one of […]
March 31, 2025
TOPLINE: Human leukocyte antigen B27 (HLA-B27) positivity was associated with higher odds of non-remission in patients with juvenile idiopathic arthritis (JIA) at 18 years after disease […]
March 27, 2025
For patients with rheumatoid arthritis, going to the doctor to discuss any ongoing symptoms or problems can be a hardship, especially if rheumatologists are scarce in […]